Early Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era

Qing‐Qing Tao,Ru Lin,Zhi‐Ying Wu

DOI: https://doi.org/10.2147/cia.s394821

IF: 3.829

2023-01-01

Clinical Interventions in Aging

Abstract:Introduction Alzheimer’s disease (AD) is the most common type of dementia in the aging population characterized by a progressive decline of cognition that brings a significant burden for patients and society. The exact pathogenesis of AD is still elusive. AD progresses along a continuum from the preclinical stage, mild cognitive, and then dementia stages. Converging lines of evidence from research studies reveal that underlying pathological changes due to AD exist in the decades before symptom onset. However, a large portion of patients remains undiagnosed at the early stages of AD in clinical practice. The early and accurate identification of AD underlying pathology is fundamental for the diagnosis, disease monitoring, and management of AD patients. Notably, early diagnosis of AD is a critical step forward for the clinical trial, which facilitates the development of disease-modifying therapies. In recent years, immense affords have been made to illustrate the early pathological changes of AD. Progress in fluid biomarkers and image analyses facilitates the early and accurate diagnostic process for AD. Based on the evidence of several core pathological changes of AD, including amyloid-β (Aβ) deposition, phosphorylated tau (p-tau), and neurodegeneration, a research framework for AD defining was proposed in 2018. However, positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers evaluations have several limitations, including high cost, insufficient accessibility, and invasiveness, stint them as a first-line AD diagnostic evaluation. Emerging blood-based biomarkers are an exciting development in this field, since they may provide a convenient, cost-effective, and less invasive screening tool.